![]() While some episodes of chest pain occurred in the context of the Immediate Post-Injection Reaction described above, many did not. Typically, the symptoms were transient and self-limited and did not require treatment however, there have been reports of patients with similar symptoms who received emergency medical care.Ĭhest Pain: Transient chest pain was noted in 13% of COPAXONE ® 20 mg per mL patients compared to 6% of placebo patients, and approximately 2% of COPAXONE ® 40 mg per mL patients compared to 1% on placebo. ![]() In general, these symptoms have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Immediate Post-Injection Reaction: Approximately 16% of patients exposed to COPAXONE ® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of patients exposed to COPAXONE ® 40 mg per mL compared to none on placebo experienced a constellation of symptoms that may occur immediately (within seconds to minutes, with the majority of symptoms observed within 1 hour) after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. Important Safety InformationĬontraindication: COPAXONE ® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol. ![]() COPAXONE ® is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |